Stockscreener 앱 받기
10.86
10.40%
-1.26
시간 외 거래:
10.80
-0.06
-0.55%
전일 마감가:
$12.12
열려 있는:
$10.99
하루 거래량:
382.31K
Relative Volume:
1.80
시가총액:
$1.61B
수익:
$7.50M
순이익/손실:
$-81.89M
주가수익비율:
0.2048
EPS:
53.0176
순현금흐름:
$-63.58M
1주 성능:
+2.94%
1개월 성능:
+4.62%
6개월 성능:
-47.31%
1년 성능:
+68.37%
1일 변동 폭
$10.81
$11.18
1주일 범위
$10.60
$12.50
52주 변동 폭
$5.78
$22.00
Mesoblast Ltd Adr Stock (MESO) Company Profile
MESO을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
MESO
Mesoblast Ltd Adr
|
10.86 | 1.61B | 7.50M | -81.89M | -63.58M | 53.02 |
|
VRTX
Vertex Pharmaceuticals Inc
|
457.03 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
547.74 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
329.77 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
545.11 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
244.32 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Mesoblast Ltd Adr Stock (MESO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-12-23 | 다운그레이드 | Jefferies | Buy → Hold |
| 2024-09-24 | 업그레이드 | Maxim Group | Hold → Buy |
| 2024-08-29 | 업그레이드 | Jefferies | Hold → Buy |
| 2024-07-23 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2023-08-31 | 업그레이드 | Jefferies | Hold → Buy |
| 2023-08-07 | 다운그레이드 | Maxim Group | Buy → Hold |
| 2023-08-04 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2023-08-04 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2023-03-09 | 개시 | William Blair | Outperform |
| 2022-12-06 | 다운그레이드 | Jefferies | Buy → Hold |
| 2022-09-06 | 개시 | Piper Sandler | Overweight |
| 2021-04-07 | 업그레이드 | Maxim Group | Hold → Buy |
| 2020-12-22 | 다운그레이드 | Maxim Group | Buy → Hold |
| 2020-12-04 | 다운그레이드 | Chardan Capital Markets | Neutral → Sell |
| 2020-10-22 | 개시 | RBC Capital Mkts | Sector Perform |
| 2020-08-14 | 재확인 | Maxim Group | Buy |
| 2020-05-28 | 재확인 | H.C. Wainwright | Buy |
| 2019-01-31 | 재개 | H.C. Wainwright | Buy |
| 2018-03-22 | 다운그레이드 | Credit Suisse | Neutral → Underperform |
| 2018-02-28 | 재확인 | Cantor Fitzgerald | Buy |
| 2017-08-31 | 개시 | Oppenheimer | Outperform |
| 2017-06-08 | 개시 | Cantor Fitzgerald | Buy |
모두보기
Mesoblast Ltd Adr 주식(MESO)의 최신 뉴스
Mesoblast Maintains Momentum With FDA on Accelerated Approval Pathway for Revascor® in Ischemic Heart Failure and Label Extension for Ryoncil® in Adults With GvHD - GlobeNewswire Inc.
All Markets & Instruments Available to Trade - Capital.com
Mesoblast (ASX:MSB) Secures Medicaid Agreement for Ryoncil® - thecapitalclub.com.au
UPDATED: Your guide to February Reporting Season 2020 - Morningstar.com.au
21 Best-Performing Small-Cap Stocks for March 2025 - NerdWallet
Why Mesoblast Ltd ADR (NASDAQ: MESO) Is Worth Including On Your Watchlist - Marketing Sentinel
The 98.76% Simple Moving Average of Mesoblast Ltd ADR’s (MESO) Stock in the Past 200 Days - The News Heater
Mesoblast Ltd ADR (NASDAQ:MESO) Shares Are Up 10.24 Percent In A Week – But Can The Gains Continue? - Marketing Sentinel
ASX Lunch Wrap: ASX and gold reset record highs; but Origin cuts its LNG forecast - Stockhead
Why are Mesoblast shares in a trading halt? - The Motley Fool Australia
Mesoblast Limited Initiates Trading Halt Pending Financing Announcement - TipRanks
ASX December health sector winners… and a 91pc drop for a trial-flopped stock - Stockhead
MESO Stock Surges 80% In A Month After FDA Approval Of GVHD Drug - Barchart
Mesoblast (NASDAQ:MESO) Shares Gap UpWhat's Next? - MarketBeat
ASX healthcare 2024 winners and losers, plus what’s next for 2025 - Stockhead
What Analysts Think About TC BioPharm (Holdings) plc ADR (NASDAQ: TCBP)’s Potential Raise - Stocks Register
NIO Inc ADR (NYSE: NIO) Stock Forecast: Could Pass $8 In A Year - Stocks Register
If You Don’t Buy Safe Pro Group Inc (NASDAQ: SPAI) Now, You’ll Regret It Later - Stocks Register
Tempest Therapeutics Inc (NASDAQ: TPST) Investors Should Be Worried About This. - Stocks Register
Mesoblast Stock Soars to 52-Week High, Hits $19.15 - Investing.com
Here’s Why Lineage Cell Therapeutics Inc (AMEX: LCTX) Is An Attractive Investment Right Now - Stocks Register
No Stopping Editas Medicine Inc (NASDAQ: EDIT)’s Stock Plunged? - Stocks Register
What Do Analysts Think About Therealreal Inc’s (NASDAQ:REAL) Future? - Stocks Register
What Awaits These 4 Biotech Stocks That More Than Doubled In 2024 - Barchart
Mesoblast shares downgraded to hold by Jefferies By Investing.com - Investing.com South Africa
Why the Mesoblast share price is diving 18% after an FDA win - The Motley Fool Australia
Mesoblast share price rockets 30% on big US FDA news - The Motley Fool Australia
Mesoblast stock soars to 52-week high, hits $12.21 - Investing.com
Mesoblast Stock Soars to 52-Week High, Hits $12.19 - Investing.com
Mesoblast stock soars to 52-week high, hits $11.1 - Investing.com
JPMorgan Takes Substantial Stake in Mesoblast Ltd - TipRanks
Mesoblast to raise $50m from top shareholder for product launch - Capital Brief
Mesoblast: Rolling The Dice On Cellular Medicines (NASDAQ:MESO) - Seeking Alpha
Check Up: Big breakthrough in acne treatment, and recent ASX biotech winners - Stockhead
11 Best ASX Stocks To Buy Now - Yahoo Finance
symbol__ Stock Quote Price and Forecast - CNN
10 Best Australian Stocks To Buy - Yahoo Finance
Australia stocks higher at close of trade; S&P/ASX 200 up 0.43% - Investing.com
Philip R. Krause, M.D., Former FDA Deputy Chief For Vaccines, Joins Mesoblast Board - Barchart
ASX dives as Trump tests COVID positive - The Australian
The Daily Biotech Pulse: Adcom Rules In Favor Of Mesoblast, CureVac IPO, Novavax Clinches UK COVID-19 Vaccine Deal - Yahoo Finance
Advantage: Australia. Biotechs Surge Ahead in Regenerative Medicine and Immuno-Oncology - streetwisereports.com
6 ASX BioTechs Trading on the NASDAQ - TheBull.com.au
Mesoblast Ltd Adr (MESO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.45%
0.86%
자본화:
|
볼륨(24시간):